![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 34, 30591-30597, August 23, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
,
,
§, and
§¶
From the
Department of Ophthalmic Research, Cole Eye
Institute, and the § Department of Cell Biology, Lerner
Research Institute, The Cleveland Clinic Foundation,
Cleveland, Ohio 44195
Received for publication, May 1, 2002, and in revised form, May 30, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Bestrophin is a 68-kDa basolateral plasma
membrane protein expressed in retinal pigment epithelial cells (RPE).
It is encoded by the VMD2 gene, which is mutated in Best
macular dystrophy, a disease characterized by a depressed light peak in
the electrooculogram. Recently it was proposed that bestrophin
is a chloride channel responsible for generating the light peak. To
investigate its function further, we immunoaffinity purified a
bestrophin complex from RPE lysates and identified bestrophin and the
Best macular dystrophy
(BMD),1 a vitelliform macular
dystrophy, is an autosomal dominant inherited disorder. Clinically, BMD is characterized by an "egg yolk" or vitelliform lesion in the macula easily visible by fundus examination (1, 2). It is thought that
the vitelliform lesion may be caused by the abnormal deposition of
lipofuscin in the retinal pigment epithelium (RPE) (3).
Histopathologically, BMD has been shown to manifest as a generalized
RPE abnormality associated with lipofuscin accumulation, regions of
geographic atrophy, and deposition of abnormal fibrillar material
beneath the RPE (3, 4). Occasional breaks in Bruch's membrane with
accompanying neovascularization have also been reported (3, 4). Many of
these features are also found in age-related macular degeneration, the
leading cause of blindness in the elderly.
Despite the histopathologic and clinical features described above, the
defining characteristic of BMD is a light peak to dark trough ratio in
the electrooculogram (EOG) less than 1.5, without aberrations in the
clinical electroretinogram (1). Otherwise asymptomatic carriers
of BMD-associated mutations will exhibit an altered EOG (5, 6). The EOG
is a late response of the eye to light and is generated by a
depolarization of the basal plasma membrane of the RPE (7). This
depolarization is thought to be caused by a Ca2+-sensitive
chloride current (7-9). Induction of the light peak requires a
"light peak substance" that is secreted by the neurosensory retina
(7). Transduction of the signal that induces the light peak thus
requires signaling across the RPE cell from a presumed receptor at the
apical surface of the cells to activate one or more chloride channels
in the basolateral plasma membrane of the RPE cell. The details of this
pathway and indeed the identity of the light peak substance are unknown.
The gene mutated in BMD, VMD2, was identified in 1998 (10,
18). To date, 79 different mutations have been identified in BMD
patients (summarized at the VMD2 mutation data base,
www.uni-wuerzburg.de/humangenetics/vmd2.html). Of these, 75 are
missense mutations resulting in substitutions at 56 different amino
acids (10-19). Two mutations are single amino acid deletions (15, 16,
18). One splice site and one frameshift mutation have been reported
(13, 15). In addition, three novel missense mutations have been
reported in cases of adult onset vitelliform macular dystrophy (11,
15). Like genes identified for other inherited macular disorders,
VMD2 mutations are rare in age-related macular degeneration
patients (11, 15, 16).
VMD2 encodes a 585-amino acid protein with an approximate
mass of 68 kDa (10, 18) which has been designated bestrophin. Bestrophin shares homology with the Caenorhabditis elegans
RFP gene family, named for the presence of a conserved arginine (R), phenylalanine (F), proline (P), amino acid sequence motif. Our laboratory has produced antibodies that recognize bestrophin and demonstrated that bestrophin is a plasma membrane protein, localized to
the basolateral surface of RPE cells (20) consistent with a role for
bestrophin in the generation or regulation of the EOG light peak.
Recently, Sun et al. (21) have provided evidence that
bestrophin and other RFP family members represent a new class of
chloride channels, indicating a direct role for bestrophin in
generating the light peak.
As a step toward understanding the function of bestrophin and how
mutations in the protein result in retinal degenerative disease, we
have immunoaffinity purified a bestrophin-containing complex from
porcine RPE. Here, we demonstrate that bestrophin interacts physically
with the serine/threonine-protein phosphatase PP2A. We also demonstrate
that bestrophin is phosphorylated and that this phosphorylation is
sensitive to PP2A and okadaic acid (an inhibitor of PP2A). These data
provide the first evidence for how bestrophin and potentially the light
peak of the EOG are regulated.
Antibodies and Western Blots--
Mouse mAb (mAb) E6-6 and
rabbit polyclonal antibody 125 recognizing human, porcine, and monkey
bestrophin are described elsewhere (20). Monoclonal antibody E6-1
recognizing human, porcine, and monkey bestrophin was produced in the
same fusion as E6-6 and exhibits properties identical to those of E6-6
(data not shown). Monoclonal antibody 1D6 recognizing the catalytic
subunit of PP2A, mAb 2G9 recognizing an epitope common to all known
PP2A B subunits, and a rabbit polyclonal IgG recognizing the A subunit
of PP2A were obtained from Upstate Biotechnology (Lake Placid, NY).
Western blots were performed as described previously (22) using
alkaline phosphatase-conjugated secondary antibodies and tetranitro
blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate.
Immunoaffinity Isolation of Bestrophin-containing
Complexes--
RPE cells were isolated from porcine eyes obtained from
Hatfield Quality Meats (Hatfield, PA) as follows. Eyes were bisected posterior to the limbus and the neurosensory retina removed. RPE cells
were gently brushed from the eyecup in
Ca2+/Mg2+-free phosphate-buffered saline using
a camel's hair brush. The cells were pelleted by centrifugation at
1,000 × g for 5-20 min at 4 °C. RPE pellets were
stored frozen at -80 °C.
For immunoaffinity purification, RPE cell pellets from 400 eyes were
lysed for 3 h at 4 °C in lysis buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl, 10% glycerol,
0.5% Nonidet P-40, 0.5% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, and a 1:100 dilution of protease
inhibitor mixture III (Calbiochem). Lysates were centrifuged at
10,000 × g for 10 min and the insoluble cell debris
discarded. Supernatants were precleared with 2.5 ml of protein
A-Sepharose CL-4B/100 ml for 2 h at 4 °C. To immunoaffinity isolate bestrophin-containing complexes, anti-bestrophin mAb E6-1 was cross-linked to protein A-Sepharose CL-4B using
dimethylpimelimidate (23) and was added to the precleared lysate.
Protein A-Sepharose CL-4B reacted with dimethylpimelimidate in the
absence of antibody was used as a control. After an overnight
incubation at 4 °C, lysates were centrifuged at 500 × g for 10 min, and the pellet was washed three times in wash
buffer (50 mM Tris, pH 8.0, 0.5% Nonidet P-40, and 1 mM phenylmethylsulfonyl fluoride) containing either low
salt (150 mM NaCl) or high salt (700 mM NaCl).
The antibody-immobilized suspension was then transferred to a column. After washing with low salt wash buffer, the bestrophin-containing complexes were eluted with 100 mM glycine, pH 2.5, and
collected into tubes containing 1 M Tris, pH 9.5. Aliquots
of samples were removed for direct analysis by Western blot. The
remaining sample was concentrated using SDS-quinine sulfate
precipitation as described previously (24) and after resuspension in
SDS-PAGE sample buffer was resolved by SDS-PAGE on a 10% gel. The gel
was stained with Gel Code Blue (Pierce), and bands were excised for
protein identification by MALDI-TOF mass spectrometry.
Mass Spectrometry and Protein Identification--
Protein bands
excised from the Gel Code Blue-stained gel were destained in 50%
acetonitrile, dried in a Speed-Vac, and rehydrated in 15 µl of 30 mM N-ethylmorpholine acetate, pH 8.6, containing 0.1 µg of tosylphenylalanyl chloromethyl ketone-modified trypsin (Promega, Madison, WI) and incubated overnight at 37 °C (25). Tryptic digests were then extracted with 60% acetonitrile containing 0.1% trifluoroacetic acid (once with 60 µl, twice with 30 µl) and
analyzed by MALDI-TOF mass spectrometry as described previously using a
PE Biosystems Voyager DE Pro instrument (25). Measured protein masses
were used to search the Swiss-Prot, TrEMBL, PIR, and NCBI sequence data
bases for protein identifications and data base accession numbers.
Bestrophin identifications were confirmed further by manual comparison
against the predicted tryptic peptide map derived from the porcine
bestrophin amino acid sequence presented in Fig. 2. The amino acid
sequence was obtained by nanoelectrospray tandem mass spectrometry
using the PE Sciex API 3000 triple quadrupole electrospray instrument
fitted with nanospray interface (MDS Proteomics A/S, Odense, Denmark)
as described elsewhere (25).
Partial Porcine Bestrophin cDNA Sequence--
A partial
cDNA for porcine bestrophin was prepared by reverse
transcription-PCR using total RNA isolated from porcine RPE cells. The
upstream primer 5'-CCAACCTGGGCAACGTGCTCATCCTGCGC-3' was designed based
on the human cDNA sequence encoding the conserved peptide
YANLGNVLILR determined by mass spectrometry (see Table I) to be present
in porcine bestrophin. The downstream primer 5'-GGCCGGTACCCTAGGAGTGTGCTTCATCCC-3' was designed based on the porcine
bestrophin sequence in an expressed sequence tag containing the C
terminus of porcine bestrophin (GenBank accession no. AW480265). The
PCR product was sequenced directly.
GST Pulldown Assay--
The GST-bestrophin fusion protein
(GST-Best) contains amino acids 334-568 of human bestrophin. To create
GST-Best, the corresponding region of human bestrophin cDNA was
amplified by PCR from a human placenta cDNA library, subcloned into
the pGEX-4T-2 vector, and verified by sequencing. The fusion protein
was expressed in BL21 bacterial cells and purified by affinity
chromatography with glutathione-Sepharose 4B as described previously
(26). GST-Best and GST bound to glutathione-Sepharose beads (40 µl of
50% slurry containing 0.5 µg of GST-Best) were added to 1 ml of
porcine retinal lysates (500 µg of total protein) that had been
precleared with 20 µl of glutathione-Sepharose. The excess amount of
GST (10 µg) was used as control for nonspecific sticking of PP2A.
After incubation for 1 h at 4 °C, the beads were pelleted and
washed three times in low salt wash buffer. The beads were then
suspended in SDS-sample buffer and analyzed by SDS-PAGE on a 10% gel
and Western blot with PP2A antibody 1D6.
Cell Culture and in Vitro Phosphorylation--
RPE-J cells were
maintained in Dulbecco's modified Eagle's medium supplemented with
4% fetal bovine serum, nonessential amino acids, glutamine, and
penicillin/streptomycin at 32 °C in an environment of 95% air and
5% CO2 as described previously (27, 28). For in
vitro phosphorylation assays, RPE-J cells were plated at
confluence (3 × 105 cells/cm2) in
six-well multiwell plates. After 24 h of growth at 32 °C, cells
were switched to 39.5 °C and transduced with the
replication-defective adenovirus AdBest, directing expression of human
bestrophin at a multiplicity of infection of 60 as described previously
(20). 24 h after transduction, the cells were washed with
phosphate-free Dulbecco's modified Eagle's medium containing 20 mM HEPES and labeled for 4 h with 800 µCi/ml
32Pi containing 0 or 100 nM okadaic
acid. Cells were then washed with phosphate-buffered saline and scraped
from the plate in ice-cold lysis buffer (1% Triton X-100, in 50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM
EDTA, 0.2% bovine serum albumin) containing 1 mM
phenylmethylsulfonyl fluoride, protease inhibitor mixture III
(Calbiochem), 50 µl of washed PANSORBIN (Calbiochem), and 0 or
100 nM okadaic acid. After 1 h the lysates were
centrifuged at 10,000 × g. Bestrophin was immunoprecipitated from the supernatants with mAb E6-1. After SDS-PAGE,
gels were dried and exposed for 30 min to a storage phosphorscreen.
Phosphorimage analysis was performed using a Molecular Dynamics Typhoon
8600 PhosphorImager and Imagequant version 5.1 software (Molecular
Dynamics, Sunnyvale, CA).
In Vitro Dephosphorylation--
Purified PP2A isolated from
human red blood cells as a heterodimer of the catalytic C and
structural A subunits was obtained from Upstate Biotechnology. The
activity of the purified enzyme was defined in units where 1 unit
releases 1 nmol phosphate/min from 15 µm
[32P]phosphorylase A at 30 °C. For the preparation of
enzyme used, 1 unit was equal to ~5 µg of protein.
RPE-J cells were transduced with AdBest and labeled with
32Pi as above. After immunoprecipitation, the
beads were washed once with 20 mM MOPS, pH 7.5, 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 0.1 mM MnCl2, containing
0.1 mg/ml bovine serum albumin (reaction buffer). The beads
were then resuspended in 195 µl of reaction buffer containing 1 mM dithiothreitol, 60 mM 2-mercaptoethanol and
divided into three 65 µl aliquots. The following reagents were added
to each tube in a 10 µl volume of reaction buffer containing 1 mM dithiothreitol, 60 mM 2-mercaptoethanol,
bringing the volume of the reaction mixture to 75 µl. To one aliquot,
no PP2A or okadaic acid was added. To a second aliquot 1 unit of
purified PP2A containing both the catalytic C and structural A subunits
(Upstate Biotechnology) was added. To the third aliquot 1 unit of
purified PP2A and 100 nM okadaic acid were added. Aliquots
were then digested for 30 min at 30 °C and the reaction terminated
by the addition of 4× SDS-sample buffer. Samples were then boiled for
5 min and resolved by SDS-PAGE. Gels were dried and exposed to Kodak
X-Omat film. Films were scanned and band intensities determined using
Imagequant 5.1 software.
Immunoaffinity Isolation of a Bestrophin Protein Complex--
To
identify proteins that interact with bestrophin we immunoaffinity
purified a bestrophin-containing complex from lysates of isolated
porcine RPE cells using mAb E6-1. As shown in Fig. 1A immunoaffinity isolates are
enriched for bestrophin, and the RPE lysate is effectively depleted of
bestrophin. Gel Code Blue staining demonstrates a similar pattern of
bands in column eluates from experiments in which the column was
washed with either 150 mM NaCl (low salt; Fig.
1B) or more stringent 700 mM NaCl (high salt;
Fig. 1C). The major band at ~68 kDa present in both high salt and low salt eluates was determined to be bestrophin by peptide mass mapping of tryptic peptides using MALDI-TOF mass spectrometry. Five peptides matched bestrophin based on the human amino acid sequence, and three additional peptides matched based on the sequence encoded by a porcine bestrophin expressed sequence tag. Two of the
peptides were confirmed to match regions of the predicted amino acid
sequence of bestrophin by amino acid sequencing using tandem mass
spectrometry (see Table
I).
Porcine Bestrophin cDNA--
To confirm further the identity
of this band as authentic porcine bestrophin we obtained a partial
cDNA encoding porcine bestrophin by reverse transcription-PCR from
porcine RPE RNA. Primers based on the peptide sequences obtained by
mass spectrometry were paired with primers based on the deduced
sequence obtained from the porcine bestrophin expressed sequence tag
for the PCR. The deduced amino acid sequence obtained from the PCR
product is aligned with the deduced human (GenBank accession no.
NM_004183) and mouse (assembled from the Celera data base, accession
no. mCG1951) bestrophin amino acid sequences in Fig.
2. As with the mouse, the porcine amino acid
sequence diverges significantly toward the C-terminal domain of the
protein. Of interest, the last 18 amino acids of the human sequence
represent the peptide against which mAbs E6-1 and E6-6 were produced
and are identical at 17 of 18 positions in the porcine sequence. In
contrast, the mouse sequence in this region is poorly conserved
explaining the species specificity of antibodies produced against this
region of the protein.
When the peptides identified by mass spectrometry were compared against
the predicted tryptic peptide map of porcine bestrophin, 14 matches
were made with the pig sequence, further confirming the identity of the
~68 kDa band as porcine bestrophin (Table I). Two of the original
peptides matching human bestrophin come from regions of the protein
which were not covered by our partial porcine cDNA.
Identification of PP2A as a Component of the Bestrophin Protein
Complex--
22 additional gel bands in the high and low salt eluates
were detected by SDS-PAGE of the bestrophin protein complex. The majority of the bands were determined to be bestrophin fragments that
probably arose from proteolysis during purification. One band at ~ 36 kDa present in both high salt and low salt eluates was
identified as the
PP2A is a heterotrimeric enzyme consisting of three subunits. In
addition to the catalytic subunit, PP2A includes a structural A subunit
(PR65) and one of many possible B subunits that appear to function in
compartmentalization of the enzyme (29, 30) (Fig.
4A). PP2A phosphatase activity is
entirely in the catalytic subunit and does not require interaction with
the other subunits (30). Western blotting of porcine RPE-lysates with
antibodies recognizing the different PP2A subunits (Fig. 4B)
indicates that all three subunits are present in RPE cells. Bestrophin
co-migrates exactly with PR65, and the B subunits exhibit masses of
50-55 kDa which co-migrate with a nonspecific band in our large scale immunoprecipitates (see Fig. 1). We did not detect PR65 or a B subunit
by MALDI-TOF mass spectrometry perhaps because the signals were not
strong enough in the mixture of peptides. We examined the interaction
of bestrophin with PR65 by immunoprecipitating bestrophin with mAb E6-1
and blotting with an anti-PR65 polyclonal antibody (Fig.
4C). PR65 was readily detected as a band that co-migrated with authentic PR65 in control samples in which PP2A was
immunoprecipitated using a mAb against PP2Ac. We conclude that
bestrophin interacts with a typical PP2A complex.
Interaction of the Cytosolic Domain of Bestrophin with
PP2A--
Bestrophin is predicted to have four membrane-spanning
Phosphorylation of Bestrophin--
PP2A is a serine/threonine
phosphatase. The interaction of bestrophin with PP2A suggests that
bestrophin might be phosphorylated and that the interaction with PP2A
may play a role in regulating the status of bestrophin phosphorylation.
To test this hypothesis we performed an in vitro labeling
with 32Pi in RPE-J cells expressing human
bestrophin. Labeling was performed in the presence or absence of 100 nM okadaic acid, an inhibitor of PP2A. After lysis of the
cells, bestrophin was immunoprecipitated and its phosphorylation status
determined by phosphorimage analysis (Fig.
6). Bestrophin was found to be readily
labeled with 32P, indicating that bestrophin is
phosphorylated. A strong signal was present in the sample in which
phosphatase inhibitors were omitted, suggesting that bestrophin
phosphorylation is relatively stable. The addition of okadaic acid to
the media during labeling and to the lysis buffer enhanced the
bestrophin phosphorylation signal by 46 ± 17% (mean ± S.D., n = 4), implying that PP2A is responsible for the dephosphorylation of a portion of phosphorylated bestrophin. To test further the ability of PP2A to dephosphorylate bestrophin, purified PP2A was used in an in vitro
dephosphorylation assay (Fig. 7). The
addition of 1 unit of PP2A to a 32P-labeled bestrophin
immunoprecipitate resulted in the reduction in the intensity of the
bestrophin band of 94.9 ± 0.4% (n = 3) relative
to the control. The addition of 100 nM okadaic acid to the
same reaction resulted in the preservation of 57 ± 14%
(n = 3) of bestrophin band intensity. These data
suggest that bestrophin phosphorylation is regulated by PP2A.
The amino acid sequence of bestrophin offers few clues to assist
in understanding the function of the protein (12). We took the approach
that by immunoaffinity-isolating bestrophin we could identify
protein-binding partners that could assist in identifying its
physiological role in the RPE cell. To this end we have isolated a
bestrophin-containing protein complex from porcine RPE and identified PP2A as a member of the complex. Reciprocal immunoprecipitation experiments have confirmed that the interaction between bestrophin and
PP2A is significant and not the result of protein contamination of our
samples or background. We have also provided evidence that PP2A
interacts with the C-terminal domain of bestrophin, that bestrophin is
phosphorylated in vitro, and that PP2A can function to
regulate the phosphorylation of bestrophin.
Addition of the PP1/PP2A inhibitor okadaic acid to RPE-J cells during
labeling and in the lysis buffer had some effect on the phosphorylation
status of bestrophin compared with a control sample in which
phosphatase inhibitors were omitted (Fig. 6). Furthermore, the addition
of purified PP2A to phosphobestrophin resulted in the near complete
dephosphorylation of the protein (Fig. 7). This was found to be okadaic
acid-sensitive. These data suggest that bestrophin phosphorylation is
sensitive to PP2A inhibitors and that the interaction between
bestrophin and PP2A may directly mediate the dephosphorylation of
bestrophin in vivo. To date we have found no evidence of
tyrosine phosphorylation of
bestrophin,2 and the near
complete dephosphorylation of bestrophin achieved with purified PP2A
(Fig. 7) suggests that bestrophin may not be substrate for tyrosine
kinases under the conditions we tested. Analysis of the human amino
acid sequence for bestrophin using NetPhos 2.0 (www.cbs.dtu.dk/services/NetPhos/) (31 and data not shown) indicates
that a large number of candidate serines, threonines, and tyrosines are
potential targets of protein kinases. A further analysis using PROSCAN
(npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_prosite.html, data not shown) found only consensus sites for
serine/threonine kinases.
Growing evidence suggests that PP2A is important in the visual system.
The cycle of phosphorylation and dephosphorylation of rhodopsin
requires the activity of PP2A (32), and PP2A has been shown to modulate
the responsiveness of the cGMP-gated Na+ channel (33) in
photoreceptors. This regulation may be involved in fine tuning of the
light response or in light or dark adaptation. Modulation of these
functions would manifest as changes that could affect the early
responses in the electroretinogram, a measure of the standing potential
of the eye. A series of well characterized changes in the
electroretinogram can be evoked using light as a stimulus. Of the five
main waveforms, the first two, the a and b waves, represent the
activity of cells in the neurosensory retina. The RPE participates in
generating the subsequent c wave and is responsible for generating the
fast oscillation trough and the light peak. These two responses also
give rise to the fast oscillation and light peak of the EOG.
BMD is characterized by a diminished light peak in the EOG. In contrast
to the other electroretinogram waveforms, the light peak is thought to
be stimulated by a secreted signal (rather than an electrical signal or
change in local ion concentration) originating in the neurosensory
retina (7). This light peak substance is presumably detected at or near
the apical surface of the RPE cell. Once stimulated, an as yet
uncharacterized signal transduction pathway carries the signal to the
opposite pole of the RPE cell where it manifests as a depolarization of
the basolateral plasma membrane. The plasma membrane depolarization is
caused by activation of a Ca2+-sensitive Cl
-catalytic subunit of protein phosphatase 2A (PP2A) as members of
the complex by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry. Protein-protein interaction between
bestrophin and PP2Ac and the structural subunit of PP2A, PR65, was
confirmed by reciprocal immunoprecipitation. The C-terminal cytoplasmic domain of bestrophin was sufficient for the interaction with PP2A as
demonstrated by a pulldown assay using a fusion of this domain with
glutathione S-transferase. Bestrophin was phosphorylated when expressed in RPE-J cells and this phosphorylation was sensitive to
okadaic acid. Purified PP2A effectively dephosphorylated bestrophin in vitro. These data suggest that bestrophin is in the
signal transduction pathway that modulates the light peak of the
electrooculogram, that it is regulated by phosphorylation, and that
phosphorylation of bestrophin is in turn regulated by PP2A.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (35K):
[in a new window]
Fig. 1.
Immunoaffinity isolation of bestrophin
complexes. Bestrophin-containing complexes were immunoaffinity
isolated from porcine RPE lysates as described under "Experimental
Procedures." A, Western blot of the lysate (L),
supernatant (S), or column eluate (E)
demonstrates the depletion of bestrophin from the supernatant incubated
with mAb E6-1 versus control. Note the enrichment for
bestrophin in the E6-1 eluate but the absence of a bestrophin band in
the control. B, Gel Code Blue-stained SDS-PAGE separating
eluates after low salt (150 mM NaCl) wash. C,
Gel Code Blue-stained SDS-PAGE separating eluates after high salt (700 mM NaCl) wash. Arrowheads indicate two major
bands present in E6-1 eluates which were not present in controls. The
heavy band at ~68 kDa was identified as bestrophin (see
Table I) and the ~36 kDa band (see Table II) as the
-catalytic
subunit of PP2A.
Peptides matching bestrophin associated with the
68 kDa gel band

View larger version (60K):
[in a new window]
Fig. 2.
Alignment of human, porcine, and mouse
bestrophin amino acid sequences. A partial cDNA encoding
porcine bestrophin was obtained as described under "Experimental
Procedures." Alignment of porcine bestrophin (p) with
human (h) and mouse (m) bestrophin amino acid
sequences indicates that porcine bestrophin is more conserved with
respect to human than mouse. In addition, the epitope corresponding to
the immunizing peptide for antibody E6-1 is identical at 17 of 18 amino
acids, whereas the mouse C terminus diverges
significantly.
-catalytic subunit of protein phosphatase 2A
(PP2Ac) by matching eight predicted tryptic peptides (Table II). To confirm the interaction
between bestrophin and PP2Ac a series of experiments was
performed in which either bestrophin or PP2Ac was immunoprecipitated
from porcine or human RPE lysates (Fig. 3).
When we immunoprecipitated with anti-bestrophin antibody, PP2Ac could
be detected by Western blots of the bestrophin immunoprecipitate (Fig.
3, left). When we precipitated with anti-PP2Ac, we
could detect bestrophin in the immunoprecipitates (Fig. 3,
right). These data confirm that bestrophin and PP2Ac
interact.
Peptides matching Sus scrofa protein phosphatase 2A catalytic subunit,
isotype associated with the
36 kDa gel band

View larger version (33K):
[in a new window]
Fig. 3.
Reciprocal immunoprecipitation of bestrophin
with an antibody against PP2A catalytic subunit. To confirm that
PP2Ac interacts with bestrophin, reciprocal immunoprecipitations
(IP) were performed. Human and porcine RPE lysates were
immunoprecipitated with either antibody 1D6 recognizing PP2Ac or E6-1
recognizing bestrophin. Immunoprecipitates were analyzed in comparison
with the original lysates. A, immunoprecipitation with
anti-PP2Ac mAb 1D6 followed by immunoblotting with anti-bestrophin mAb
E6-1. In both human and porcine lysates, anti-PP2Ac antibody 1D6
efficiently coimmunoprecipitated bestrophin and enriched it with
respect to the original lysate. B, immunoprecipitation with
anti-bestrophin mAb E6-1 followed by immunoblotting with anti-PP2Ac mAb
1D6. Consistent with Fig. 1, E6-1 recognizing bestrophin efficiently
coimmunoprecipitated PP2Ac.

View larger version (25K):
[in a new window]
Fig. 4.
Interaction of bestrophin with the PP2A
structural subunit PR65. A, heterotrimeric structure of
PP2A. A structural A subunit (PR65) serves to link the catalytic C
subunit to a B subunit. Western blot analysis of porcine RPE lysates
(B) with polyclonal antibodies against PP2Ac, B subunits
(PP2Ab), PR65, and bestrophin, demonstrates that PR65 co-migrates with
bestrophin on SDS-PAGE. The B subunits exhibit a mass of 50-55 kDa,
similar to the major nonspecific band in the large scale
immunoprecipitations (see Fig. 1). C demonstrates that PR65
is present in immunoprecipitates (IP) of bestrophin
(Best) or PP2Ac but is absent from controls in which lysates
were incubated with protein A beads alone.
-helices and a large C-terminal cytoplasmic region. We next sought to determine whether the C-terminal region is responsible for the
interaction between bestrophin and PP2Ac using a GST pulldown assay. In this experiment, we incubated a porcine retina lysate with a
fusion of GST and the C-terminal domain of bestrophin (GST-Best), or
with GST alone (Fig. 5A). Porcine
retinal lysates were used instead of porcine RPE lysates because
neurosensory retina does not express endogenous bestrophin. Thus, all
of the PP2A in retina is free of bestrophin prior to incubation with
GST-Best. GST-Best or GST and their associated proteins were isolated
from the lysates with glutathione-Sepharose and then blotted with an
antibody recognizing bestrophin (Fig. 5B) or PP2Ac (Fig.
5C). PP2Ac immunoreactivity was present only in the
sample incubated with GST-Best and not in the sample from lysates
incubated with GST alone (Fig. 5C). These data further
confirm the interaction of bestrophin and PP2A and imply that this
interaction occurs with the cytosolic C-terminal region of
bestrophin.

View larger version (27K):
[in a new window]
Fig. 5.
GST pulldown assay with the C-terminal domain
of bestrophin. Lysates of porcine neurosensory retina were
incubated with either a purified fusion of GST and the C-terminal
domain of bestrophin (GST-Best) or purified GST, and then proteins were
isolated with glutathione-Sepharose. A, Gel Code blue stain
of purified GST and GST-Best. Note that GST-Best is not very stable,
and substantial breakdown products are visible. B, Western
blot of purified GST-Best and GST with mAb E6-1 demonstrating that
bestrophin immunoreactivity is only associated with the GST-Best
fusion. C, Western blot of glutathione-Sepharose pulldowns
from incubated lysates demonstrating that PP2Ac is brought down by
GST-Best but not by GST. These data imply that PP2Ac interacts with the
cytosolic C-terminal domain of bestrophin.

View larger version (30K):
[in a new window]
Fig. 6.
Phosphorylation of bestrophin. RPE-J
cells transduced with AdBest at a multiplicity of infection of 0 or 60 were labeled with 32Pi in the presence
(OA +) or absence (OA
) of 100 nM
okadaic acid, an inhibitor of PP2A. After immunoprecipitation with mAb
E6-1, bestrophin was resolved by SDS-PAGE, and the phosphorylation
status was determined by phosphorimage analysis. Bestrophin was
observed to be phosphorylated. Note an increase in the intensity of the
bestrophin band by ~25% in the presence of okadaic acid.

View larger version (16K):
[in a new window]
Fig. 7.
In vitro dephosphorylation of
bestrophin by PP2A. RPE-J cells transduced with AdBest at a
multiplicity of infection of 0 or 60 were labeled with
32Pi, and bestrophin immunoprecipitated from
cell lysates as indicated under "Experimental Procedures."
Immunoprecipitates were digested for 30 min at 30 °C with 0 or 1 unit of PP2A and 0 or 100 nM okadaic acid (OA).
Bestrophin was then resolved by SDS-PAGE, and the gel was dried and
exposed to film. As shown in A, addition of PP2A to the
sample resulted in a significant reduction in bestrophin
phosphorylation. Addition of okadaic acid to the sample together with
PP2A substantially inhibited the PP2A-mediated dephosphorylation of
bestrophin. Data in B are the mean ± S.D. for three
independent experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
conductance (7). Recently Sun et al. (21) provided evidence that bestrophin may function as a Ca2+-sensitive chloride
channel. The implication of their data is that bestrophin generates the
conductance that gives rise to the light peak and so is at the last
step of this signal transduction pathway. The interaction of bestrophin
and PP2A suggests that phosphorylation or dephosphorylation of
bestrophin may act as the on/off switch for the light peak or modulate
its amplitude or timing. Investigations aimed at elucidating the
relationship between bestrophin phosphorylation and the light peak may
help to explain how mutations in bestrophin result in BMD.
| |
ACKNOWLEDGEMENTS |
|---|
We thank George Hoppe and Nicole Kyle for assistance in preparing porcine RPE and Zhenglin Yang for DNA sequencing.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants R01 EY13160 (to A. D. M.) and R01 EY06603 (to J. W. C.), a Kirchgessner Foundation research grant (to A. D. M.), and the Foundation Fighting Blindness (to J. W. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AY064707.
¶ To whom correspondence should be addressed: Dept. of Ophthalmic Research, Cole Eye Institute-i31, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-444-5822; Fax: 216-445-3670; E-mail: marmora@ccf.org.
Published, JBC Papers in Press, June 10, 2002, DOI 10.1074/jbc.M204269200
2 L. Y. Marmorstein, P. J. McLaughlin, J. B. Stanton, L. Yan, J. W. Crabb, and A. D. Marmorstein, unpublished observation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: BMD, best macular dystrophy; EOG, electrooculogram; GST, glutathione S-transferase; mAb, monoclonal antibody; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; MOPS, 4-morpholinepropanesulfonic acid; PP2A, protein phosphatase 2A; PP2Ac, catalytic subunit of PP2A; RPE, retinal pigment epithelial.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Cross, H. E., and Bard, L. (1974) Am. J. Ophthalmol. 77, 46-50[Medline] [Order article via Infotrieve] |
| 2. | Gass, D. J. M. (1997) in Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment (Gass, D. J. M., ed), Vol. 1 , pp. 303-313, Mosby, St. Louis |
| 3. | Weingeist, T. A., Kobrin, J. L., and Watzke, R. C. (1982) Arch. Ophthalmol. 100, 1108-1114[Abstract] |
| 4. | O'Gorman, S., Flaherty, W. A., Fishman, G. A., and Berson, E. L. (1988) Arch. Ophthalmol. 106, 1261-1268[Abstract] |
| 5. | Maloney, W. F., Robertson, D. M., and Duboff, S. M. (1977) Arch. Ophthalmol. 95, 979-983[Abstract] |
| 6. | Bard, L. A., and Cross, H. E. (1975) Trans. Am. Acad. Ophthalmol. Otolaryngol. 79, OP865-OP873[Medline] [Order article via Infotrieve] |
| 7. | Gallemore, R. P., Hughes, B. A., and Miller, S. S. (1998) in The Retinal Pigment Epithelium (Marmor, M. F. , and Wolfensberger, T. J., eds) , pp. 175-198, Oxford University Press, New York |
| 8. |
Gallemore, R. P.,
and Steinberg, R. H.
(1993)
J. Neurophysiol.
70,
1669-1680 |
| 9. | Gallemore, R. P., and Steinberg, R. H. (1989) J. Neurosci. 9, 1977-1984[Abstract] |
| 10. | Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., Vujic, M., Bergen, A. A., McGarty-Dugan, V., Figueroa, D., Austin, C. P., Metzker, M. L., Caskey, C. T., and Wadelius, C. (1998) Nat. Genet. 19, 241-247[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Allikmets, R., Seddon, J. M., Bernstein, P. S., Hutchinson, A., Atkinson, A., Sharma, S., Gerrard, B., Li, W., Metzker, M. L., Wadelius, C., Caskey, C. T., Dean, M., and Petrukhin, K. (1999) Hum. Genet. 104, 449-453[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Bakall, B., Marknell, T., Ingvast, S., Koisti, M. J., Sandgren, O., Li, W., Bergen, A. A., Andreasson, S., Rosenberg, T., Petrukhin, K., and Wadelius, C. (1999) Hum. Genet. 104, 383-389[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Caldwell, G. M., Kakuk, L. E., Griesinger, I. B., Simpson, S. A., Nowak, N. J., Small, K. W., Maumenee, I. H., Rosenfeld, P. J., Sieving, P. A., Shows, T. B., and Ayyagari, R. (1999) Genomics 58, 98-101[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Eksandh, L., Bakall, B., Bauer, B., Wadelius, C., and Andreasson, S. (2001) Ophthalmic Genet. 22, 107-115[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Kramer, F., White, K., Pauleikhoff, D., Gehrig, A., Passmore, L., Rivera, A., Rudolph, G., Kellner, U., Andrassi, M., Lorenz, B., Rohrschneider, K., Blankenagel, A., Jurklies, B., Schilling, H., Schutt, F., Holz, F. G., and Weber, B. H. (2000) Eur. J. Hum. Genet. 8, 286-292[CrossRef][Medline] [Order article via Infotrieve] |
| 16. |
Lotery, A. J.,
Munier, F. L.,
Fishman, G. A.,
Weleber, R. G.,
Jacobson, S. G.,
Affatigato, L. M.,
Nichols, B. E.,
Schorderet, D. F.,
Sheffield, V. C.,
and Stone, E. M.
(2000)
Invest. Ophthalmol. Visual Sci.
41,
1291-1296 |
| 17. | Marchant, D., Gogat, K., Boutboul, S., Pequignot, M., Sternberg, C., Dureau, P., Roche, O., Uteza, Y., Hache, J. C., Puech, B., Puech, V., Dumur, V., Mouillon, M., Munier, F. L., Schorderet, D. F., Marsac, C., Dufier, J. L., and Abitbol, M. (2001) Hum. Mutat. 17, 235[Medline] [Order article via Infotrieve] |
| 18. |
Marquardt, A.,
Stohr, H.,
Passmore, L. A.,
Kramer, F.,
Rivera, A.,
and Weber, B. H.
(1998)
Hum. Mol. Genet.
7,
1517-1525 |
| 19. | Palomba, G., Rozzo, C., Angius, A., Pierrottet, C. O., Orzalesi, N., and Pirastu, M. (2000) Am. J. Ophthalmol. 129, 260-262[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Marmorstein, A. D.,
Marmorstein, L. Y.,
Rayborn, M.,
Wang, X.,
Hollyfield, J. G.,
and Petrukhin, K.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
12758-12763 |
| 21. |
Sun, H.,
Tsunenari, T.,
Yau, K. W.,
and Nathans, J.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
4008-4013 |
| 22. |
Marmorstein, L. Y.,
Ouchi, T.,
and Aaronson, S. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13869-13874 |
| 23. | Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual , 1st Ed. , pp. 521-527, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 24. | McKinley, M. P., Bolton, D. C., and Prusiner, S. B. (1983) Cell 35, 57-62[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | West, K., Yan, L., Miyagi, M., Crabb, J. S., Marmorstein, A. D., Marmorstein, L. Y., and Crabb, J. W. (2001) Exp. Eye Res. 73, 479-491[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Marmorstein, L. Y., Kinev, A. V., Chan, G. K., Bochar, D. A., Beniya, H., Epstein, J. A., Yen, T. J., and Shiekhattar, R. (2001) Cell 104, 247-257[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Nabi, I. R., Mathews, A. P., Cohen-Gould, L., Gundersen, D., and Rodriguez-Boulan, E. (1993) J. Cell Sci. 104, 37-49[Abstract] |
| 28. | Marmorstein, A. D., Bonilha, V. L., Chiflet, S., Neill, J. M., and Rodriguez-Boulan, E. (1996) J. Cell Sci. 109, 3025-3034[Abstract] |
| 29. | Janssens, V., and Goris, J. (2001) Biochem. J. 353, 417-439[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Virshup, D. M. (2000) Curr. Opin. Cell Biol. 12, 180-185[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Blom, N., Gammeltoft, S., and Brunak, S. (1999) J. Mol. Biol. 294, 1351-1362[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Kutuzov, M. A., and Bennett, N. (1996) Eur. J. Biochem. 238, 613-622[Medline] [Order article via Infotrieve] |
| 33. | Gordon, S. E., Brautigan, D. L., and Zimmerman, A. L. (1992) Neuron 9, 739-748[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
H. C. Hartzell, Z. Qu, K. Yu, Q. Xiao, and L.-T. Chien Molecular Physiology of Bestrophins: Multifunctional Membrane Proteins Linked to Best Disease and Other Retinopathies Physiol Rev, April 1, 2008; 88(2): 639 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. McLaughlin, B. Bakall, J. Choi, Z. Liu, T. Sasaki, E. C. Davis, A. D. Marmorstein, and L. Y. Marmorstein Lack of fibulin-3 causes early aging and herniation, but not macular degeneration in mice Hum. Mol. Genet., December 15, 2007; 16(24): 3059 - 3070. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. A. Mandal, V. Vasireddy, G. B. Reddy, X. Wang, S. E. Moroi, B. R. Pattnaik, B. A. Hughes, J. R. Heckenlively, P. F. Hitchcock, M. M. Jablonski, et al. CTRP5 Is a Membrane-Associated and Secretory Protein in the RPE and Ciliary Body and the S163R Mutation of CTRP5 Impairs Its Secretion Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5505 - 5513. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lecuona, L. A. Dada, H. Sun, M. L. Butti, G. Zhou, T.-L. Chew, and J. I. Sznajder Na,K-ATPase {alpha}1-subunit dephosphorylation by protein phosphatase 2A is necessary for its recruitment to the plasma membrane FASEB J, December 1, 2006; 20(14): 2618 - 2620. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. McLaughlin, Q. Chen, M. Horiguchi, B. C. Starcher, J. B. Stanton, T. J. Broekelmann, A. D. Marmorstein, B. McKay, R. Mecham, T. Nakamura, et al. Targeted disruption of fibulin-4 abolishes elastogenesis and causes perinatal lethality in mice. Mol. Cell. Biol., March 1, 2006; 26(5): 1700 - 1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ayyagari, M. N. A. Mandal, A. J. Karoukis, L. Chen, N. C. McLaren, M. Lichter, D. T. Wong, P. F. Hitchcock, R. C. Caruso, S. E. Moroi, et al. Late-Onset Macular Degeneration and Long Anterior Lens Zonules Result from a CTRP5 Gene Mutation Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3363 - 3371. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Strauss The Retinal Pigment Epithelium in Visual Function Physiol Rev, July 1, 2005; 85(3): 845 - 881. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Loewen and G. W. Forsyth Structure and Function of CLCA Proteins Physiol Rev, July 1, 2005; 85(3): 1061 - 1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Campos, V. Forjaz, L. R. Kozak, E. Silva, and M. Castelo-Branco Quantitative Phenotyping of Chromatic Dysfunction in Best Macular Dystrophy Arch Ophthalmol, July 1, 2005; 123(7): 944 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tsunenari, H. Sun, J. Williams, H. Cahill, P. Smallwood, K.-W. Yau, and J. Nathans Structure-Function Analysis of the Bestrophin Family of Anion Channels J. Biol. Chem., October 17, 2003; 278(42): 41114 - 41125. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bakall, L. Y. Marmorstein, G. Hoppe, N. S. Peachey, C. Wadelius, and A. D. Marmorstein Expression and Localization of Bestrophin during Normal Mouse Development Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3622 - 3628. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||